Skip to main content
Premium Trial:

Request an Annual Quote

Agenix Licenses Tyrian Dx Technology to Develop Microarray Device

NEW YORK (GenomeWeb News) – Australian diagnostics and biopharmaceutical firm Agenix announced today it is licensing a rapid point-of-care diagnostic technology from Tyrian Diagnostics for development of a microarray device.

Agenix will use Tyrian's DiagnosticIQ platform for human applications. Bayer CropScience currently licenses the technology for agricultural applications.

Agenix is providing Tyrian A$500,000 (US$517,000) in shares of its stock to be paid in installments through June 2014.

DiagnosticIQ comprises a disposable test device that can be used alone or with the DiagnosticIQ Reader. Agenix plans to develop a microarray device based on the technology, which would allow human health diagnostic tests to be processed on the one system, Agenix said.

The terms of the deal also provide Agenix a patent for Tyrian's antibody-based test for active tuberculosis.

"This acquisition advances our product pipeline and adds to our human health diagnostics business," Agenix Chairman and CEO Nicholas Weston said in a statement. "We now have a platform for human health arrays and microarray technology developers globally, as well as a medical device product for our expanding China business."

Based in Melbourne, Australia, Agenix also has a subsidiary, Agenix Biopharmaceutical, based in Shanghai.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.